Samuel Granjeaud

Dr. Samuel Granjeaud

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Current Biology
Verified
Journal Article
Closed access
GMGustavo V. Mallo
Gustavo V. Mallo
CKC.Léopold Kurz
C.Léopold Kurz
CCCarole Couillault
Carole Couillault
NPNathalie Pujol
Nathalie Pujol
SGSamuel Granjeaud
Samuel Granjeaud
JEJonathan J. Ewbank
Jonathan J. Ewbank

1 September 2003 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MBMarc BajénOff
Marc BajénOff
SGSamuel Granjeaud
Samuel Granjeaud
SGSylvie Guerder
Sylvie Guerder
The development of an immune response critically relies on the encounter of rare antigen (Ag)-specific T cells with dendritic cells (DCs) presenting the relevant Ag. How two rare cells find each other in the midst of irrelevant other cells in lymph nodes (LNs) is unknown. Here we show that initial T cell activation clusters are generated near high endothelial venules (HEVs) in the outer paracortex of draining LNs by retention of Ag-specific T cells as they exit from HEVs. We further show that tissue-derived DCs preferentially home in the vicinity of HEVs, thus defining the site of cluster generation. At this location DCs efficiently scan all incoming T cells and selectively retain those specific for the major histocompatibility complex–peptide complexes the DCs present. Such strategic positioning of DCs on the entry route of T cells into the paracortex may foster T cell–DC encounter and thus optimize initial T cell activation in vivo.

4 October 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JLJulie Leca
Julie Leca
SMSébastien Martinez
Sébastien Martinez
SLSophie Lac
Sophie Lac
JNJérémy Nigri
Jérémy Nigri
VSVéronique Secq
Véronique Secq
Richard TomasiniRichard Tomasini
Richard Tomasini
The intratumoral microenvironment, or stroma, is of major importance in the pathobiology of pancreatic ductal adenocarcinoma (PDA), and specific conditions in the stroma may promote increased cancer aggressiveness. We hypothesized that this heterogeneous and evolving compartment drastically influences tumor cell abilities, which in turn influences PDA aggressiveness through crosstalk that is mediated by extracellular vesicles (EVs). Here, we have analyzed the PDA proteomic stromal signature and identified a contribution of the annexin A6/LDL receptor-related protein 1/thrombospondin 1 (ANXA6/LRP1/TSP1) complex in tumor cell crosstalk. Formation of the ANXA6/LRP1/TSP1 complex was restricted to cancer-associated fibroblasts (CAFs) and required physiopathologic culture conditions that improved tumor cell survival and migration. Increased PDA aggressiveness was dependent on tumor cell–mediated uptake of CAF-derived ANXA6+ EVs carrying the ANXA6/LRP1/TSP1 complex. Depletion of ANXA6 in CAFs impaired complex formation and subsequently impaired PDA and metastasis occurrence, while injection of CAF-derived ANXA6+ EVs enhanced tumorigenesis. We found that the presence of ANXA6+ EVs in serum was restricted to PDA patients and represents a potential biomarker for PDA grade. These findings suggest that CAF–tumor cell crosstalk supported by ANXA6+ EVs is predictive of PDA aggressiveness, highlighting a therapeutic target and potential biomarker for PDA.

14 April 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
CPChristine Pasero
Christine Pasero
GGGwenaëlle Gravis
Gwenaëlle Gravis
MGMathilde Guerin
Mathilde Guerin
SGSamuel Granjeaud
Samuel Granjeaud
JTJeanne Thomassin-Piana
Jeanne Thomassin-Piana
DODaniel Olive
Daniel Olive
The field of immunotherapy for solid tumors, such as prostate cancer, has been recently focusing on therapies that can counter tumor-mediated immunosuppression. Precise quantification and characterization of the immune infiltrates in tumors is crucial to improve treatment efficacy. Natural killer (NK) cells, major components of the antitumor immune system, have never been isolated from prostate tumors, despite their suspected role in disease progression. Here, we examined the frequency, phenotype, and functions of NK cells infiltrating control and tumor prostate tissues. NK cell infiltrates in prostate tissues were mainly CD56 (NCAM1)-positive and displayed an unexpected immature, but activated, phenotype with low or no cytotoxic potential. Furthermore, we show that TGFβ1 (TGFB1) is highly secreted into the prostate environment and partly mediates the immunosuppressive effects on NK cells. In addition to this basal level of immunotolerance to NK cells, the prostate environment became further resistant to NK cell–mediated immunity upon cancer cell infiltration. Coculture experiments revealed that prostate cancer cells induced the expression of inhibitory receptor (ILT2/LILRB1) and downregulated the expression of activating receptors NKp46 (NCR1), NKG2D (KLRK1), and CD16 (FCGR3) by NK cells, thus preventing their recognition of tumor cells. Notably, blood levels of NKp46 were also decreased in prostate cancer patients and were inversely correlated with levels of prostate-specific antigen, the main prognostic factor in prostate cancer. Our study shows that a strong immunosuppressive environment impairs NK cell function at multiple levels in prostate cancer and provides a rationale for the design of therapies that restore NK cell efficiency in the prostate tumor microenvironment. Cancer Res; 76(8); 1–13. ©2016 AACR.

29 April 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
CPChristine Pasero
Christine Pasero
GGGwenaëlle Gravis
Gwenaëlle Gravis
SGSamuel Granjeaud
Samuel Granjeaud
MGMathilde Guerin
Mathilde Guerin
JTJeanne Thomassin-Piana
Jeanne Thomassin-Piana
DODaniel Olive
Daniel Olive
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer

1 December 2000 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
FBFrançois Bertucci
François Bertucci
RHRémi Houlgatte
Rémi Houlgatte
ABAthmane Benziane
Athmane Benziane
SGSamuel Granjeaud
Samuel Granjeaud
JAJosé Adélaïde
José Adélaïde
CNCatherine Nguyen
Catherine Nguyen
Breast cancer is characterized by an important histoclinical heterogeneity that currently hampers the selection of the most appropriate treatment for each case. This problem could be solved by the identification of new parameters that better predict the natural history of the disease and its sensitivity to treatment. A large-scale molecular characterization of breast cancer could help in this context. Using cDNA arrays, we studied the quantitative mRNA expression levels of 176 candidate genes in 34 primary breast carcinomas along three directions: comparison of tumor samples, correlations of molecular data with conventional histoclinical prognostic features and gene correlations. The study evidenced extensive heterogeneity of breast tumors at the transcriptional level. A hierarchical clustering algorithm identified two molecularly distinct subgroups of tumors characterized by a different clinical outcome after chemotherapy. This outcome could not have been predicted by the commonly used histoclinical parameters. No correlation was found with the age of patients, tumor size, histological type and grade. However, expression of genes was differential in tumors with lymph node metastasis and according to the estrogen receptor status; ERBB2 expression was strongly correlated with the lymph node status (P < 0.0001) and that of GATA3 with the presence of estrogen receptors (P < 0.001). Thus, our results identified new ways to group tumors according to outcome and new potential targets of carcinogenesis. They show that the systematic use of cDNA array testing holds great promise to improve the classification of breast cancer in terms of prognosis and chemosensitivity and to provide new potential therapeutic targets.